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To describe the geographic variation in anti-osteoporosis drug therapy prescriptions before 
and after a hip fracture during 1999-2013 in the UK. 
 
Methods 
We used primary care data (Clinical Practice Research Datalink) to identify patients with a 
hip fracture and primary care prescriptions of any anti-osteoporosis drugs prior to the index 
hip fracture and up to five years after. Geographic variations in prescribing before and after 
availability of generic oral bisphosphonates were analysed. Multivariable logistic regression 
models were adjusted for gender, age and body mass index (BMI).  
 
Results  
13,069 patients (76% female) diagnosed with a hip fracture during 1999-2013 were 
identified. 11% had any anti-osteoporosis drug prescription in the six months prior to the 
index hip fracture. In the 0-4 months following a hip fracture 5% of patients were prescribed 
anti-osteoporosis drugs in 1999, increasing to 51% in 2011 to then decrease to 39% in 2013.  
 
The independent predictors (OR (95%CI)) of treatment initiation included gender (male:0.42 
(0.36-0.49)), BMI (0.98 per kg/m2 increase (0.97-1.00)) and geographic region (1.29 (0.89-
1.87) North East vs. 0.56(0.43-0.73) South Central region). Geographic differences in 
prescribing persisted over the 5-year follow-up. If all patients were treated at the rate of the 
highest performing region, then nationally an additional 3,214 hip fracture patients would be 
initiated on therapy every year.  
 
Conclusions 
Significant geographic differences exist in prescribing of anti-osteoporosis drugs after hip 
fracture despite adjustment for potential confounders. Further work examining differences in 
health care provision may inform strategies to improve secondary fracture prevention after 
hip fracture.  
 
Mini Abstract  
Fragility fractures of the hip have a major impact on the lives of patients and their families. 
This study highlights significant geographical variation in secondary fracture prevention with 
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even the highest performing regions failing the majority of patients despite robust evidence 
supporting the benefits of diagnosis and treatment. 
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Fragility fractures of the hip are associated with significant morbidity, increased risk of 
subsequent falls and other fractures as well as higher mortality [1-3]. About 87,000 hip 
fractures occur annually in the UK, mostly in elderly individuals with underlying bone fragility 
as a result of osteoporosis. Almost half of all hip fracture patients have had a prior fracture 
[2]. The estimated risk of a second hip fracture ranges from 2.3% to 10.6%, with the majority 
of second hip fractures occurring within a few years after the first [4]. One-year mortality 
estimates following fracture range from 8.4% to 36% [2]. 
 
Anti-osteoporosis drugs (e.g. bisphosphonates) and interventions to help patients to avoid 
falls can potentially halve the risk of further hip fractures[5]. Persistence with anti-
osteoporotic drug therapy is important for reducing the number of secondary fractures, and 
discontinuing therapy is associated with a 32% increase in fracture risk [6]. Despite cost 
effective medicines that reduce re-fracture [7], there has been a failure to translate research 
evidence and guidance into routine clinical care with reported low rates of prescribing for 
patients surviving a hip fracture [8]. We have previously demonstrated a significant increase 
in treatment initiation following the availability of generic bisphosphonates and publication of 
national guidance for secondary fracture prevention (Hawley 2016 submitted).  
 
Geographic variations in health care delivery have been used to inform health care policy [9]. 
Geographical variation that remains after adjustment for demographic factors is unlikely to 
be due to differences in disease prevalence or patient preferences. UK health care policy 
places duties on health services to reduce variations in access to, and outcomes from, 
health care services for patients, and to assess and report on how well they have fulfilled this 
duty . The aim of the study was to describe geographic variation in prescription of anti-





Primary care data from the Clinical Practice Research Datalink (CPRD) were used to identify 
patients with a hip fracture. The CPRD covers 11.3 million people from 674 UK practices, 
with a current coverage of approximately 6.9% of the UK population who are broadly 
representative of the UK population in terms of age, sex and ethnicity [10]. The Office for 
National Statistics database on mortality was linked and validated with the data within 
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CPRD. While the data is anonymised at the participant level, geographical information is 
recorded by dividing the UK into 13 geographic regions.  
 
Study Population 
Hip fractures occurring between 1 January 1999 and 30 September 2013 among patients 
over the age of 60 years were identified using READ codes as defined a priori after 
consensus by two clinicians experienced in clinical practice and epidemiological research 
[11]. To ensure that primary not secondary hip fractures had been captured, patients had to 
have no record of a hip fracture in the three years preceding the identified hip fracture.  
The treatment outcomes were defined as the proportion of patients who were treated with 
anti-osteoporosis medications 6 months prior to hip fracture, within 4 months of primary hip 
fracture and up to five years after were calculated for each geographical region. Patients 
who died or who were lost to follow-up prior to the relevant time periods were not included. 
Medications classified as ‘anti-osteoporosis’ included oral bisphosphonates, hormone 
replacement therapy (HRT), selective oestrogen receptor modulators (SERMS), strontium 
ranelate, denosumab and teriparatide. Outcomes were also stratified by gender and 
calendar period of primary hip fracture (1999-2004 vs. 2005-2013), reflecting the availability 
of generic bisphosphonates and national guidelines for secondary fracture prevention 
The main predictor was geographical region, which is pre-defined in CPRD, and extracted at 
the patient level. A priori, we use the region with the largest number of cases as the referent 
region, the North West. The following potential confounders were also extracted: gender and 
calendar period of primary hip fracture, body mass index (BMI, kg/m2), socio-economic 
status (Index of Multiple Deprivation 2004), Charlson Index of Comorbidity, other specific 
comorbid conditions, smoking status (current, Ex, and non-smoker) and drinking status 
(current, Ex, and non-drinker) and other previous non-hip fractures.  
 
Statistical analysis 
Descriptive statistical techniques were used to present variations in prevalence of 
prescribing by geographical region combining both incident and prevalent users in pre-
defined time periods before and after the index fracture. Multiple imputation using chained 
equations was used to account for missing data on body mass index, smoking and drinking 
[12]. Twenty imputed datasets were generated using all potential factors (including the 
outcome) and estimated parameters were combined using Rubin’s rules. Many patients had 
missing data on Index of Multiple Deprivation (41%), which was defined as ‘missing not at 
random’ because the score can only be calculated for patients in England. This factor was 




Independent risk factors for prescription with an anti-osteoporosis medicine were identified 
using multivariable logistic regression models. All potential predictors were assessed in 
univariate models, and then in multivariable models using backward-stepwise selection. A 
parsimonious multivariable model was identified from the full model using cut-offs of p- entry 
0.049 and p- exit 0.10. Univariate and multivariate models were applied to patients with 
complete data (N=6,019) and the imputed data for all patients (N=13,069). A sensitivity 
analysis was conducted on the imputed datasets for patients who had data on Index of 
Multiple Deprivation (N=7,676), which resulted in similar odds ratios as those for the imputed 
data for all patients. 
 
An additional sensitivity analysis was conducted using Fine and Gray survival regression 
models to take into account the competing risk of mortality [13]. Patients were censored at 




A cohort of 13,069 patients diagnosed with a primary hip fracture during 1999-2013 was 
identified in CPRD; their descriptive factors are described in Table 1. Following the index hip 
fracture, mortality was high with 14% of patients dying within 4 months and an additional 8% 
dying within a year. 
 
Overall, rates of prescribing of anti-osteoporosis drugs in the 6 months prior to index hip 
fracture were very low (11%) with no significant geographical variation (Figure 1). 
Geographic differences in prior prescription did not predict prescribing patterns following hip 
fracture.  
 
Nationally, in the 0-4 months following a hip fracture 5% of patients were prescribed an anti-
osteoporosis drug in 1999, which increased to 51% in 2011 (p<0.001) and significantly 
decreased to 39% in 2013 (p<0.001).  
 
During the entire study period (1999-2013) independent predictors of treatment initiation 
included men (OR=0.43 95% CI: 0.39-0.49, p=<0.001), increasing BMI (OR=0.98 95%CI: 
0.97-0.99, p=0.002) and region (OR=1.44 95% CI: 1.10-1.88, p=0.008 North East vs. 
OR=0.77 95%CI: 0.64-0.93, p=0.006 South Central, with North West region as reference 
category) (Table 2).  If all patients were treated at the rate of the highest performing region, 





There was a significant interaction between geographic region and calendar period of hip 
fracture (p=0.0047) (Table 3). During 1999-2004, overall 10% of patients with a primary hip 
fracture were prescribed anti-osteoporosis drugs within 4 months with little variation by 
geographic region (Figure 2a). However during 2005-2013, this increased to 40% with 
marked variations between regions (50% of the patients in the North East compared with 
34% of patients in the South Central region) (Figure 2b). The percentage of patients on anti-
osteoporosis drugs both in the 0-6 months pre and 0-4 post hip fracture increased from 59% 
to 75% from 1999-2004 to 2005-2013. Further, the percentage of patients who were on anti-
osteoporosis drugs before their hip fracture and then stopped immediately aftewarrds, 
reduced from 41% to 25% between these time periods.  
 
Following an index hip fracture, there was a significant decline in prescription rates such that 
by 5 years only 15% were on any anti-osteoporosis therapy (Figures 2a and 2b). Regional 
differences in prescribing persisted over the 5-year follow-up; 10% of patients were on 
therapy at five years in the South Central region in contrast with those in the North East 
(25%) and in Northern Ireland (27%) during 2005-13. While there was a significant difference 
in medication initiation by calendar year, the overall prescribing rates at 5 years were similar 
between 1999-2004 and 2005 – 2013 (15.9% vs. 15.8%, respectively). Models adjusting for 
the competing risk of death produced similar findings (see supplementary table).  
 
Discussion 
Summary of key findings 
This study has confirmed significant geographic variation in initiation of anti-osteoporosis 
medication after hip fracture in the UK. However, even the best performing geographical 
region had lower initiation rates than anticipated and longer-term prescribing of therapy 
remained low.  
 
Geographical variation of care  
Geographical variation in health care use has been used for many decades to highlight 
areas for further investigation and potentially significant change in routine clinical care.  
Historically, the description of an upto eightfold difference in tonsillectomy between 
comparable towns within England and USA [14] led to dis-investment in tonsillectomy and 
subsequent clinical trials to identify the subgroups who do benefit. More recent reviews of 
studies of geographical variation have confirmed its value to highlight a potential priorities for 
evidence synthesis and/or dissemination to inform local commissioning with the aims of 
standardising current practice around current best evidence [9]. While typically applied to 
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high volume procedures, geographical variation in care has been shown to also apply where 
there is underuse of healthcare [15]. Variation in care has been identified in a number of 
disease areas including radiotherapy for cancer [16], ischaemic heart disease[17] but not 
childhood asthma[18].-,  
 
The major drivers of geographical variation in health care delivery are a) difference in 
physicians’ ability to diagnose patients b) difference in physicians’ belief in the benefits of the 
intervention [19]. These are underpinned by variation in technology diffusion [20] and gaps in 
the clinical knowledge of clinicians or how they apply their knowledge [21].  In case of the 
tonsillectomy in the early 20th Century, the geographical variation in physicians’ diagnosis 
and treatment was due to the lack of trial evidence for the intervention. In contrast, the 
observed variation in secondary fracture prevention is not due to a lack of robust evidence 
for how to diagnose high-risk patients or the lack of evidence for the treatment benefit and 
likely reflects inadequate technology diffusion.  
 
A number of tools have been validated to identify and diagnose patients at high risk that 
would benefit from pharmacotherapy such as FRAX [22] and Qfracture [23]. The National 
Osteoporosis Guidance Group recommendations deliver treatment thresholds within FRAX 
as a decision aid to support physicians in the diagnosis of patients who would benefit from 
therapy [24]. The FRAX tool has now been tested in a large scale randomized controlled trial 
and demonstrated an impressive 24% reduction in hip fracture associated with an 80% 
prescription rate in those identified at high risk vs. 12% in the control group [25]. The lower 
treatment rates and lack of difference in the pre-fracture period suggests a) selection and 
maintainence of anti-osteoporosis prescriptions in high risk patients who go on to fracture is 
poor in primary care b) post-fracture variation in secondary fracture prevention most likely 
reflects the variable presence of fracture liaison services within the UK [26]. 
 
 
Another issue is the belief of benefit of secondary fracture prevention amongst the wider 
health care community and policy makers. Despite a number of trials demonstrating fracture 
reduction from 20 to 70% using anti-osteoporosis medications [5] and the cost-effectiveness 
of these interventions [27], secondary fracture prevention in the UK remains poor with less 
than a third of the expected number of patients treated for secondary fracture prevention 
included in the UK Quality Outcome Framework in 2013/14, a national re-imbursement 
scheme for primary care [28]. Further, recently published perspectives in general medical 
journals, based on opinion and not the balance of published literature [29], have questioned 
the effectiveness of pharmacotherapy for secondary fracture prevention causing confusion 
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over the benefits of secondary prevention denying high risk patients therapy and leading to 
avoidable fragility fractures to the detriment of patients, their family, carers and the society 




While in the randomized controlled trials used to register agents, persistence with therapy 
was over 90% [30], real world data has consistently described poor persistence in the real 
world setting with rates of primary non-adherence of up to 30% [31] and secondary non-
adherence between 30 and 50% at one year [32]. Persistance has been reported as higher 
in the one year after fragility fracture but still low in those aged 80 and over[33]. Non-
adherence to anti-osteoporosis medication is associated with a 30- 40% increase in the risk 
of fracture [6]. In this study, the geographic variation in medication prescriptions persisted 
from initiation to 5 years after the index fracture. However the higher rates of medication 
initiation after 2005 did not translate to higher rates of prescriptions at 5 years across 
geographical regions. The poor adherence to anti-osteoporosis therapies is well known and 
monitoring has been recognized as one of the essential components for a secondary 
fracture prevention care pathway to be effective [34]. The most efficient methods for 
monitoring have yet to be determined. The major reasons for lack of persistence with oral 
bisphosphonates, the first line anti-osteoporosis therapy used in most cases, include patient 
characteristics (experiencing side effects, insufficient motivation, lack of perceived benefit 
and the complex administration [35]) and physician characteristics (overestimation of patient 
adherence [36] and physician misinformation [35]),  
 
Improving medication persistence to anti-osteoporosis therapy is challenging. A number of 
strategies such as providing reminders [37], motivational telephone interventions [38], 
personal training using telephone calls and group meetings [39] have been tested and do 
not improve treatment persistence to anti-osteoporosis. However, the longer treatment 
interval and simpler administration regimes with denosumab have been shown to increase 
12-month persistence rates to over 80% in routine clinical practice [40, 41].  
 
Secondary fracture prevention care gap and Fracture Liaison Services 
International bodies such as the ASBMR and IOF [42, 43] have published guidelines on 
service models to improve secondary fracture prevention to reduce subsequent fractures 
[44]. These recommendations recommend that Fracture Liaison Services be created to close 
the care gap in secondary fracture prevention. However,  in the UK, less than 40% of 
hospitals in England had established such a service by 2010 and there is marked variability 
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in service delivery with more than 50% of services identifying less than 50% of their 
expected fragility fracture caseload annually[26]. Published criteria and standards are now 
available as part of an improvement programme to improve the quality of Fracture Liaison 
Services and ensure they are both effective and efficient[45]. 
 
 
Strengths and Limitations 
This is a large study using real world data that used validated methods to ascertain the 
primary fracture. Two statistical methods were used to analyse the data given we did not 
know how mortality may differ in the data. As competing risk methods such as Fine & Grey 
need to be used if the mortality rates differ between exposure groups, and mortality after hip 
fracture did not vary by region, both Cox and Fine & Grey gave similar findings. Regional 
denominators were not available and so the proportion of patients presenting with a hip 
fracture per region is not known. While primary care data in the UK captures prescribing of 
oral anti-osteoporosis medication, the prescribing of parenteral therapies such as 
teriparatide, zoledronate and denosumab is likely underestimated, as a proportion will be 
prescribed in the secondary care setting with inconsistent recording in the primary care 
record. This may account for some of the differences in prescribing rates between 2011 and 
2013. While we did not have access to dispensing data and, from other sources, the rates of 
primary non-adherence is up to 30%[31]. in the UK if a patient does not pick up their 
prescription then the pharmacy feeds this back to the primary care physician and future 
scripts are not issued and these patients would be identified as non-adherent. 
 
Conclusions 
Fragility fractures of the hip have a major impact on the lives of patients and their families as 
well as to health care and society. This study highlights significant geographical variation in 
secondary fracture prevention with even the highest performing regions failing the majority of 
patients despite robust evidence supporting the benefits of diagnosis and treatment. Further 
health services research including the use of guidelines and decision aids are needed to 
close this care gap and prevent avoidable fragility fractures and their clinical and economic 
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Figure 1: Percentage of patients on any anti-osteoporosis medicine 6 months prior to 
primary hip fracture and 0-4 months following primary hip fracture by geographical 
region within the Clinical Practice Research Datalink, 1999-2013, UK 
Legend: Bars show the percentage of patients prescribed any anti-osteoporosis medication 
in the 6 months prior to and within 4 months post index hip fracture.  
Figure 2: Prescription rates of any anti-osteoporosis medication after primary hip fracture by 
geographical region during 1999-2004 (2a) and during 2005-13 (2b) within the 
Clinical Practice Research Datalink, UK 
Legend: This figure shows for each time period, the proportion of patients alive and followed 





Table 1: Baseline characteristics among primary hip fracture patients within the Clinical 
Practice Research Datalink during 1999-2013, UK 
Characteristic   Number  % 
Calendar period of hip fracture 1999-2004         5,738            44  
  2005-2013         7,331            56  
        
Gender Female         9,995            76  
  Male         3,074            24  
        
Age at hip fracture 60-69 years         1,199              9  
  70-79 years         3,291            25  
  80-89 years         6,095            47  
  ≥90 years         2,484            19  
        
Body Mass Index (kg/m2) <18.5            864              7  
  18.5-24.9         5,352            41  
  25.0-29.9         3,169            24  
  30-34.9            944              7  
  ≥35            236              2  
  Missing         2,504            19  
        
Index of Multiple Deprivation 
(quintile of deprivation) Affluent         1,694            13  
2         1,812            14  
  3         1,491            11  
  4         1,550            12  
  Deprived         1,129              9  
  Missing         5,393            41  
        
Smoking No         7,343            56  
  Yes         1,697            13  
  Ex         3,021            23  
  Missing         1,008              8  
        
Drinking Yes         7,261            56  
  No         3,391            26  
  Ex            349              3  
  Missing         2,068            16  
        
Charlson co-morbidity index  0         6,737  52 
  1         2,250  17 
  2         1,979  15 
  ≥3         2,103  16 
        
Region East Midlands            783              6  
17 
 
  East of England         1,363            10  
  London            977              7  
  North East            338              3  
  North West         1,921            15  
  Northern Ireland            678              5  
  Scotland            681              5  
  South Central         1,031              8  
  South East Coast         1,277            10  
  South West         1,323            10  
  Wales            922              7  
  West Midlands         1,104              8  
  Yorkshire & the Humber            671              5  
        
Co-morbid conditions Asthma         1,796            14  
  Malabsorption Syndromes              21              0  
  Inflammatory Bowel Disease            189              1  
  Hypertension         6,568            50  
  Hyperlipidaemia         1,884            14  
  Ischemic heart disease         2,816            22  
  Cerebro-Vascular Disease         1,453            11  
  Chronic Obstructive Pulmonary Disorder         1,214              9  
  Chronic Renal Failure            712              5  
  Cancer         2,674            20  
        
Previous fractures Previous Spinal fracture            178              1  
  Previous Wrist fracture         1,270            10  
  Previous Humerus fracture              67              1  
  Previous Pelvis fracture            187              1  
  Previous Rib fracture            321              2  
  Previous Other non-hip fracture             699              5  
        
Previous joint replacement           1,143              9  
        
Mortality 0-4 months         1,854            14  





Table 2: Estimated odds ratios (OR) of patients receiving a prescription within 4 months of primary hip fracture within the Clinical Practice 
Research Datalink, 1999-2013, UK 
 
      Complete case analysis N = 6,019   
Multiple Imputed data on BMI, smoking and drinking 
N=13,069 
          Univariate   Multivariate P value     
Univariate 
N=13,069   Multivariate P value 
Characteristic     Number % OR 
95% 
CI   OR 95% CI     % OR 95% CI   OR 95% CI   
Region (ref: North 
West) East Midlands   256 4 0.94 
0.70-
1.26   1.00 
0.73-
1.37 0.990   6 0.76 
0.62-
0.92   0.81 
0.66-
1.00 0.053 
  East of England   854 14 0.93 
0.77-
1.13   0.86 
0.70-
1.07 0.179   10 0.83 
0.71-
0.97   0.89 
0.75-
1.06 0.203 
  London   476 8 0.95 
0.75-
1.19   0.92 
0.71-
1.18 0.496   7 1.08 
0.91-
1.28   1.08 
0.90-
1.30 0.426 
  North East   153 3 1.33 
0.94-
1.89   1.26 
0.87-
1.84 0.224   3 1.34 
1.04-
1.71   1.44 
1.10-
1.88 0.008 
  North West   
        
1,183  20 1.00     1.00       15 1.00 
 
  1.00     
  
Northern 
Ireland                     5 1.19 
0.98-
1.44   1.18 
0.96-
1.45 0.125 
  Scotland                     5 0.94 
0.77-
1.14   0.91 
0.74-
1.12 0.381 
  South Central   463 8 0.69 
0.54-
0.88   0.56 
0.42-
0.73 <0.001   8 0.82 
0.69-





Coast   598 10 0.87 
0.70-
1.07   0.82 
0.64-
1.04 0.098   10 0.98 
0.84-
1.15   0.99 
0.84-
1.18 0.926 
  South West   916 15 0.93 
0.77-
1.12   0.91 
0.74-
1.11 0.353   10 0.90 
0.76-
1.05   0.93 
0.78-
1.10 0.395 
  Wales                     7 0.96 
0.81-
1.15   0.96 
0.79-
1.16 0.665 
  West Midlands   746 12 0.90 
0.74-
1.10   0.88 
0.70-
1.09 0.228   8 0.90 
0.76-




Yorkshire & the 
Humber 374 6 1.07 
0.83-
1.37   1.07 
0.82-
1.40 0.628   5 0.93 
0.76-
1.13   1.06 
0.86-
1.32 0.580 
Calendar period of hip 
fracture 1999-2004   
        
2,170  36 1.00     1.00       44 1.00     1.00     
  2005-2013   
        
3,849  64 5.52 
4.76-
6.41   6.00 
5.15-
7.00 <0.001   56 5.67 
5.14-
6.25   6.14 
5.55-
6.79 <0.001 
Gender Female   
        
4,547  76 1.00     1.00       76 1.00     1.00     
  Male   
        
1,472  24 0.46 
0.40-
0.53   0.42 
0.36-
0.50 <0.001   24 0.50 
0.45-





Age at hip fracture 
(years) 60-69 years   537 9 0.76 
0.62-
0.93   0.86 
0.69-
1.08 0.206   9 0.85 
0.74-
0.98   0.95 
0.81-
1.11 0.520 
  70-79 years   
        
1,567  26 0.89 
0.78-
1.01   1.01 
0.88-
1.17 0.859   25 0.97 
0.89-
1.07   1.11 
1.00-
1.24 0.043 
  80-89 years   
        
2,858  47 1.00     1.00       47 1.00     1.00     
  >90 years   
        
1,057  18 0.71 
0.60-
0.83   0.59 
0.50-
0.70 <0.001   19 0.70 
0.63-
0.78   0.61 
0.54-
0.69 <0.001 
Body Mass Index (kg/m2) prior to hip 
fracture       0.98 
0.97-
0.99   0.98 
0.97-
0.99 0.005   100 0.99 
0.98-
1.00   0.98 
0.97-
0.99 0.002 
Index of Multiple Deprivation quintile 
(ref=affluent)       0.96 
0.92-
0.99   0.93 
0.89-
0.97 0.003                 
Smoking Non-smoker   
        
3,614  60 1.00     1.00       61 1.00     1.00     
  Current   762 13 0.77 
0.65-
0.93   0.89 
0.73-
1.09 0.260   14 0.83 
0.74-
0.94   0.92 
0.80-
1.06 0.236 
  Ex-smoker   
        
1,643  27 1.00 
0.88-
1.13   1.00 
0.87-
1.16 0.970   25 1.14 
1.04-
1.25   1.03 
0.93-
1.14 0.573 
Drinking Current   
        
4,135  69 1.00     1.00       66 1.00     1.00     
  Non-drinker   
        
1,683  28 1.04 
0.92-
1.18   0.95 
0.83-
1.09 0.494   31 1.01 
0.92-
1.10   0.92 
0.83-
1.02 0.121 
  Ex-drinker   201 3 0.93 
0.68-
1.28   0.81 
0.58-
1.14 0.224   3 0.99 
0.78-




index (ref=0)         0.99 
0.96-
1.02   0.95 
0.92-
0.99 0.004   100 1.01 
0.98-
1.03   0.95 
0.93-
0.98 <0.001 
Co-morbid conditions Hypertension   3337 55 1.38 
1.23-
1.54   1.17 
1.03-
1.32 0.016   50 1.49 
1.37-
1.61   1.20 
1.10-
1.31 <0.001 
Previous fractures Spine fracture   106 2 1.89 
1.28-
2.78   1.83 
1.20-
2.79 0.005   1 2.32 
1.72-





fracture   29 <1 2.19 
1.06-
4.55   2.90 
1.32-
6.37 0.008   1 1.98 
1.22-





fracture    350 6 1.38 
1.10-
1.72   1.41 
1.10-
1.80 0.006   5 1.44 
1.22-




Legend: Odds Ratios (OR) shown for complete case and multiply imputed univariate and mutually adjusted Cox models. 
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Table 3:  Estimated odds ratios (OR) of patients receiving a prescription within 4 months of primary hip fracture by region and calendar period 
of diagnosis within the Clinical Practice Research Datalink, 1999-2013, UK 
  1999-2004   2005-2013 
Region OR 95% CI P value   OR 95% CI P value 
East Midlands 0.87 0.56-1.33 0.513   0.79 0.62-1.01 0.057 
East of England 1.42 1.02-1.97 0.037   0.76 0.62-0.92 0.006 
London 1.09 0.74-1.60 0.665   1.07 0.87-1.33 0.51 
North East 1.40 0.82-2.38 0.221   1.48 1.08-2.03 0.015 
North West (Referent) 1.00       1.00     
Northern Ireland 1.37 0.90-2.11 0.144   1.14 0.90-1.44 0.284 
Scotland 1.47 0.98-2.22 0.062   0.77 0.60-0.98 0.033 
South Central 0.92 0.62-1.38 0.694   0.73 0.59-0.90 0.004 
South East Coast 0.94 0.65-1.37 0.748   1.01 0.83-1.23 0.922 
South West 0.93 0.65-1.34 0.707   0.93 0.77-1.14 0.493 
Wales 0.65 0.42-1.02 0.062   1.04 0.84-1.29 0.700 
West Midlands 0.74 0.49-1.13 0.158   0.95 0.78-1.17 0.634 
Yorkshire & the 
Humber 1.06 0.69-1.62 0.790   1.07 0.83-1.38 0.599 
 






Supplementary table 1: 
 
Table 4: Estimated sub-hazard ratios (SHR) receiving a prescription within 4 months of primary hip fracture within the Clinical Practice 
Research Datalink, 1999-2013  
  
              Number Unadjusted  Adjusted model
Characteristic     SHR 95% CI P value   SHR 95% CI 
P 
value 
Region East Midlands  783  0.81 0.68 0.96 0.016   0.82 0.68 
0.9
8 0.031 
  East of England  1,363  0.84 0.73 0.97 0.016   0.88 0.75 
1.0
2 0.085 
  London  977  1.01 0.87 1.18 0.852   0.95 0.81 
1.1
1 0.532 
  North East  338  1.28 1.04 1.57 0.022   1.28 1.02 
1.6
1 0.035 
  North West  1,921  1.00         1.00       
  Northern Ireland  678  1.17 1.00 1.38 0.057   1.13 0.95 
1.3
5 0.176 
  Scotland  681  0.94 0.79 1.11 0.457   0.89 0.74 
1.0
7 0.200 





  South East Coast  1,277  0.92 0.80 1.06 0.241   0.87 0.75 
1.0
1 0.064 
  South West  1,323  0.87 0.76 1.00 0.052   0.87 0.75 
1.0
1 0.064 




  West Midlands  1,104  0.89 0.77 1.04 0.134   0.86 0.74 
1.0
0 0.052 
  Yorkshire & the Humber  671  0.97 0.82 1.15 0.712   1.05 0.88 
1.2
6 0.555 
Year of hip fracture 1999-2004  5,738  1.00         1.00       





Gender Female  9,995  1.00         1.00       





Age at hip fracture 60-69 years  1,199  0.90 0.79 1.02 0.092   0.91 0.80 
1.0
4 0.185 
  70-79 years  3,291  1.01 0.93 1.10 0.808   1.07 0.98 
1.1
7 0.136 
  80-89 years  6,095  1.00         1.00       





Body Mass Index (kg/m2) prior to hip fracture  10,565   0.99  0.98 1.00 0.013   0.99 0.98 
1.0
0 0.004 
Index of Multiple Deprivation quintile (ref=affluent)  7,676   0.97  0.94 1.00 0.045           
Smoking Non-smoker  7,343  1.00         1.00       
  Current  1,697  0.87 0.78 0.97 0.011   0.96 0.85 
1.0
8 0.534 
  Ex-smoker  3,021  1.07 0.98 1.16 0.12   0.98 0.90 
1.0
7 0.652 
Drinking Current  7,261  1.00         1.00       
  Non-drinker  3,391  1.01 0.94 1.1 0.752   0.93 0.85 
1.0
1 0.078 
  Ex-drinker 349 0.96 0.77 1.19 0.686   0.82 0.66 
1.0
2 0.076 







Co-morbid conditions Hypertension  6,568  1.41 1.31 1.51 <0.001   1.12 1.04 
1.2
1 0.004 
Previous fractures Spine fracture 178 1.81 1.44 2.27 <0.001   1.46 1.15 
1.8
6 0.002 








Legend: Odds Ratios (OR) shown for complete case and multiply imputed univariate and mutually adjusted Fine and Gray competing risk 
model.  
